Business Context and Reporting Period
This Form 6-K filing by Intercure Ltd. covers the month of November 2025, specifically dated November 3, 2025. The report serves to disseminate a press release regarding a new strategic partnership.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. This report is a disclosure of a corporate event rather than a financial statement.
Material Changes
The primary material event disclosed is the signing of Strategic Investment and Collaboration Agreements between Intercure Ltd. and Cannasoul. The stated objective of this agreement is to advance cannabis science and pharmaceutical innovation.
Guidance, Outlook, and Risks
Management Commentary: The company highlights the strategic nature of the collaboration to drive innovation in the pharmaceutical sector.
Outlook: The filing implies a focus on future scientific and pharmaceutical advancements through this partnership.
Risks and Contingencies: The filing text does not explicitly detail specific risks, contingencies, or unusual items associated with this agreement.
Investor Verification Checklist
- Verify the specific terms of the investment and collaboration agreements with Cannasoul (refer to Exhibit 99.1).
- Assess the potential financial impact of the Cannasoul partnership on future revenue streams.
- Review the strategic fit of this collaboration with Intercure's existing pharmaceutical pipeline.
- Confirm the regulatory status of the proposed cannabis science initiatives in relevant jurisdictions.